logo
Plus   Neg
Share
Email

EMCOR Group Boosts FY19 Outlook - Quick Facts

While reporting financial results for the first quarter, EMCOR Group, Inc. (EME) on Tuesday raised its full-year 2019 guidance for earnings and revenue, based on year-to-date performance, favorable project mix and assuming the continuation of current market conditions.

For fiscal 2019, the company now projects earnings in a range of $5.00 to $5.50 per share, up from the prior guidance range of $4.70 to $5.40 per share. The company also raised its revenue outlook to between $8.5 billion to $8.6 billion from the previous guidance range of $8.3 billion to $8.4 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.27 per share on revenues of $8.36 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
RELATED NEWS
Follow RTT
>